CurifyLabs bags €12M to automate personalised medicine
Finnishhealth technology company CurifyLabs has raised €12 million in a Series Afunding round to expand its operations in the United States and accelerate thedevelopment of its platform for personalis... CurifyLabs has secured Series A funding to expand its operations in the US, strengthen its supply chain and accelerate development of its platform for automated, personalised medicine manufacturing. Healthtech CurifyLabs bags €12M to automate personalised medicine CurifyLabs has secured Series A funding to expand its operations in the US, strengthen its supply chain and accelerate development of its platform for automated, personalised medicine manufacturing.
Key Takeaways
- Tamara Djurickovic 2 hours ago Share Share Send email Copy link Finnish health technology company CurifyLabs has raised €12 million in a Series A funding round to expand its operations in the United States and accelerate the development of its platform for personalised medicine manufacturing.
The round was co-led by Sandwater and HealthCap , with participation from Tesi (Finnish Industry Investment Ltd.
- Founded in 2021, CurifyLabs develops technology for automated pharmaceutical compounding.
Its Compounding System Solution combines proprietary software, GMP-manufactured excipient bases and three-dimensional printing technology to automate the preparation of personalised medicines.
- As the company expands, it plans to invest further in its supply chain to support its growing network of pharmacy partners.
Commenting on the company's growth and future plans, Charlotta Topelius , founder and CEO of CurifyLabs, said: This investment reflects the conviction our partners have in what we're building.
- The funding will be used to expand the company's US operations, strengthen its supply chain, enhance customer support and accelerate product development.
The funding will also support continued development of the CurifyLabs platform, including its latest product, the PharmaPrinter Aurum.
- What would you like us to deliver to you?
Stats & Key Facts
- #Finnishhealth technology company CurifyLabs has raised €12 million in a Series Afunding round to expand its operations in the United States and accelerate thedevelopment of its platform for personalis...
- #Tamara Djurickovic 2 hours ago Share Share Send email Copy link Finnish health technology company CurifyLabs has raised €12 million in a Series A funding round to expand its operations in the United States and accelerate the development of its platform for personalised medicine manufacturing.
CurifyLabs has secured Series A funding to expand its operations in the US, strengthen its supply chain and accelerate development of its platform for automated, personalised medicine manufacturing. Healthtech CurifyLabs bags €12M to automate personalised medicine CurifyLabs has secured Series A funding to expand its operations in the US, strengthen its supply chain and accelerate development of its platform for automated, personalised medicine manufacturing. Tamara Djurickovic 2 hours ago Share Share Send email Copy link Finnish health technology company CurifyLabs has raised €12 million in a Series A funding round to expand its operations in the United States and accelerate the development of its platform for personalised medicine manufacturing.
The round was co-led by Sandwater and HealthCap , with participation from Tesi (Finnish Industry Investment Ltd. ), existing investor Lifeline Ventures, as well as customers and employees in the United States. Founded in 2021, CurifyLabs develops technology for automated pharmaceutical compounding.
Its Compounding System Solution combines proprietary software, GMP-manufactured excipient bases and three-dimensional printing technology to automate the preparation of personalised medicines. The platform is designed to improve the consistency, precision and speed of compounding compared with conventional manual pharmacy processes and includes integrated quality control features. CurifyLabs said its technology is used by pharmacies in twenty-one US states and across Europe to prepare personalised medications.
For more details please read the original article at Tech.eu.
Continue Learning
Comments
Sign in to join the conversation